Company Filing History:
Years Active: 2005-2009
Title: Innovations by Phil Thompson in Therapeutic Compounds
Introduction
Phil Thompson is an accomplished inventor based in Melbourne, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic compounds. With a total of three patents to his name, Thompson's work focuses on innovative solutions for various health conditions.
Latest Patents
Thompson's latest patents include therapeutic morpholino-substituted compounds. These compounds, specifically morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives, inhibit phosphoinositide (PI) 3-kinase. This enzyme plays a crucial role in regulating platelet-adhesion processes. The inhibition of PI 3-kinase leads to anti-thrombotic activity and other beneficial pharmaceutical properties. The compounds are represented by specific formulas and are designed to treat a range of PI 3-kinase-dependent conditions. These include cardiovascular diseases such as coronary artery occlusion and stroke, respiratory diseases like asthma and COPD, inflammatory disorders, and various cancers.
Career Highlights
Throughout his career, Phil Thompson has worked with notable companies, including AstraZeneca and Kinacia Pty. Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Thompson has collaborated with several professionals in his field, including Alan Duncan Robertson and Shaun P Jackson. These collaborations have likely enhanced his research and development efforts.
Conclusion
Phil Thompson's innovative work in therapeutic compounds showcases his dedication to advancing medical science. His patents reflect a commitment to addressing critical health issues through targeted pharmaceutical solutions.